To send content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about sending content to .
To send content items to your Kindle, first ensure firstname.lastname@example.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about sending to your Kindle.
Note you can select to send to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
In the Mitoxantrone in Multiple Sclerosis (MIMS) study, patients were enrolled between 1993 and 1997 at 17 centers in Belgium, Germany, Hungary, and Poland, and randomly assigned to treatment with mitox. Cardiac monitoring, electrocardiography (ECG), and left ventricular ejection fraction (LVEF) assessed by echocardiography or radionuclide scan, was performed before treatment. The comparative study of mitox efficacy profile in relapsing-remitting multiple sclerosis (RRMS) and secondary-progressive multiple sclerosis (SPMS) evaluated the clinical and neuroradiological response to mitox. Substantial tolerability data are available from oncology studies in which mitox was generally used in combination with cyclophosphamide, luorouracil, mitomycin, methotrexate, and radiotherapy for leukemia, non-Hodgkin's lymphoma and solid tumors, and from MS studies in which mitox was used as monotherapy. The available data from studies in patients with MS suggest that mitox may have a role to play in the management of aggressive disease, as an induction therapy.
Email your librarian or administrator to recommend adding this to your organisation's collection.